NEW YORK, February 12 -- Lion Bioscience has licensed its SRS biotechnology platform to AstraZeneca, the company said today.
By taking a global perpetual license, the pharmaceutical company will have access to Lion's SRS integration software as well as the SRS Relational module.
Financial terms of the deal were not disclosed.
Since December, Lion has rolled out a series of SRS licensing announcements, including deals with Italy's Siena Biotech, Eli Lilly and Company, Johnson & Johnson Pharmaceutical Research and Development, and Cellzome.
The Heidelberg, Germany-based bioinformatics company restructured last year, cutting nearly 200 jobs and closing its drug discovery operations.